Top 5 Stocks to Buy Now
→ Where to Put $100 Before Trump's New Tech Law Rolls Out (From Brownstone Research) (Ad)tc pixel Free BIVIW Stock Alerts

BioVie (BIVIW) Competitors

BioVie logo
$0.39 -0.04 (-9.09%)
As of 06/25/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

BIVIW vs. SXTPW, DRTSW, APLMW, CDIOW, and CELUW

Should you buy BioVie stock or one of its competitors? MarketBeat compares BioVie with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioVie include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), Cardio Diagnostics (CDIOW), and Celularity (CELUW). These companies are all part of the "biotechnology" industry.

How does BioVie compare to 60 Degrees Pharmaceuticals?

BioVie (NASDAQ:BIVIW) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, BioVie had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for BioVie and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat BioVie's score of 0.94 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Positive
60 Degrees Pharmaceuticals Very Positive

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats BioVie on 2 of the 3 factors compared between the two stocks.

How does BioVie compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTSW) and BioVie (NASDAQ:BIVIW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, Alpha Tau Medical had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Alpha Tau Medical and 2 mentions for BioVie. Alpha Tau Medical's average media sentiment score of 0.96 beat BioVie's score of 0.94 indicating that Alpha Tau Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alpha Tau Medical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioVie
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
Alpha Tau MedicalN/A N/A N/A
BioVie N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Tau MedicalN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Summary

Alpha Tau Medical beats BioVie on 2 of the 2 factors compared between the two stocks.

How does BioVie compare to Apollomics?

Apollomics (NASDAQ:APLMW) and BioVie (NASDAQ:BIVIW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
BioVie N/A N/A N/A

In the previous week, Apollomics and Apollomics both had 2 articles in the media. Apollomics' average media sentiment score of 0.94 equaled BioVie'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apollomics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioVie
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Apollomics beats BioVie on 1 of the 1 factors compared between the two stocks.

How does BioVie compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIOW) and BioVie (NASDAQ:BIVIW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$16.57KN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Cardio DiagnosticsN/A N/A N/A
BioVie N/A N/A N/A

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 2 articles in the media. Cardio Diagnostics' average media sentiment score of 1.43 beat BioVie's score of 0.94 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Cardio Diagnostics Positive
BioVie Positive

Summary

Cardio Diagnostics beats BioVie on 2 of the 2 factors compared between the two stocks.

How does BioVie compare to Celularity?

BioVie (NASDAQ:BIVIW) and Celularity (NASDAQ:CELUW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
Celularity$26.55MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Celularity N/A N/A N/A

In the previous week, BioVie and BioVie both had 2 articles in the media. BioVie's average media sentiment score of 0.94 beat Celularity's score of 0.30 indicating that BioVie is being referred to more favorably in the media.

Company Overall Sentiment
BioVie Positive
Celularity Neutral

Summary

BioVie and Celularity tied by winning 1 of the 2 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIVIW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIVIW vs. The Competition

Export
MetricBioVieBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$482.70M$6.61B$12.27B
Dividend YieldN/A3.86%2.67%5.89%
P/E RatioN/A3.1825.7623.97
Price / SalesN/A7,044.34553.2899.36
Price / CashN/A13.1346.3353.91
Price / BookN/A90.6210.706.32
Net IncomeN/A-$96.07M$3.57B$337.22M
7 Day Performance18.29%1.86%0.79%-1.25%
1 Month Performance25.16%0.64%0.22%-0.63%
1 Year PerformanceN/A71.08%30.84%27.95%

BioVie Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIVIW
BioVie
N/A$0.39
-9.3%		N/AN/A$0.00N/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
flat		N/A-40.1%$0.00$1.00MN/A2
DRTSW
Alpha Tau Medical
N/A$1.96
flat		N/A+913.3%$0.00N/AN/A80
APLMW
Apollomics
N/A$0.01
flat		N/A-61.0%$0.00$8.50MN/A59
CDIOW
Cardio Diagnostics
N/A$0.02
flat		N/A+29.6%$0.00$16.57KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BIVIW) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX IPO “cancelled”?
SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...
InvestorPlace | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
The EPA just put a kill switch on Elon’s empire
A federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...
Behind the Markets | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Quick favor to ask you
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Millionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.
Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel